Published: 04th July 2020
Researchers find antibodies that could shield kids from rare, polio-like disease
There is no specific treatment for AFM, which tends to strike in the late summer or early fall and which has been associated with some deaths
Researchers have identified human antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.
The illness, called acute flaccid myelitis (AFM), causes sudden weakness in the arms and legs following a fever or respiratory illness.
More than 600 cases have been identified since the US Centres for Disease Control and Prevention began tracking the disease in 2014.
"We were excited to isolate potent human antibodies that inhibit this devastating polio-like virus, and these studies will form the basis for taking them forward to clinical trials," said James Crowe, Professor at Vanderbilt University School of Medicine in the US.
There is no specific treatment for AFM, which tends to strike in the late summer or early fall and which has been associated with some deaths.
However, the disease has recently been linked to a group of respiratory viruses called enterovirus D68 (EV-D68).
Researchers at the Vanderbilt Vaccine Center isolated antibody-producing blood cells from the blood of children who had previously been infected by EV-D68.
By fusing the blood cells to fast-growing myeloma cells, the researchers were able to generate a panel of monoclonal antibodies that potently neutralised the virus in laboratory studies.
Researchers at Purdue University determined the structure of the antibodies, which shed light on how they specifically recognise and bind to EV-D68.
One of the antibodies protected mice from respiratory and neurologic disease when given either before or after infection by the enterovirus, said the study published in the journal Science Immunology.
"Studying infectious disease from a very basic level and applying the results in an animal model of disease is very powerful; hopefully, our studies will translate to a future therapeutic for this disease in children," said Richard Kuhn, Professor at Purdue University.